Prestige Consumer Healthcare (NYSE:PBH) Releases FY 2025 Earnings Guidance

Prestige Consumer Healthcare (NYSE:PBH) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided EPS guidance of 4.500-4.500 for the period, compared to the consensus EPS estimate of 4.440. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.

Prestige Consumer Healthcare Stock Performance

Prestige Consumer Healthcare stock opened at $75.90 on Thursday. The firm has a market capitalization of $3.75 billion, a P/E ratio of 18.47, a P/E/G ratio of 2.15 and a beta of 0.50. The stock has a fifty day moving average price of $79.29 and a two-hundred day moving average price of $75.25. Prestige Consumer Healthcare has a 52-week low of $60.00 and a 52-week high of $86.36. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.56 and a quick ratio of 2.10.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings data on Thursday, February 6th. The company reported $1.22 earnings per share for the quarter, topping the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. As a group, analysts anticipate that Prestige Consumer Healthcare will post 4.46 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently issued reports on PBH. DA Davidson reaffirmed a “buy” rating and set a $95.00 price target on shares of Prestige Consumer Healthcare in a research note on Monday, November 11th. Sidoti lowered shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 target price on the stock. in a research note on Monday, December 9th. StockNews.com upgraded shares of Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research report on Friday, January 24th. Finally, Raymond James upgraded shares of Prestige Consumer Healthcare to a “moderate buy” rating in a report on Thursday, December 19th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $85.25.

Insider Activity at Prestige Consumer Healthcare

In other news, insider William P’pool sold 8,987 shares of the stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $81.85, for a total transaction of $735,585.95. Following the completion of the transaction, the insider now directly owns 20,058 shares in the company, valued at $1,641,747.30. This represents a 30.94 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Ronald M. Lombardi sold 10,875 shares of the company’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total value of $898,275.00. Following the sale, the chief executive officer now owns 320,952 shares in the company, valued at $26,510,635.20. The trade was a 3.28 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 38,810 shares of company stock valued at $3,187,300. 1.60% of the stock is owned by insiders.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.